about
Cardiovascular changes during chronic hypertensive statesAspirin resistance--pharmacological mechanisms and clinical implicationsbeta-Adducin polymorphisms, blood pressure, and sodium excretion in three European populationsHypertension types defined by clinic and ambulatory blood pressure in 14 143 patients referred to hypertension clinics worldwide. Data from the ARTEMIS study.Electrophysiological study in a patient with Fabry disease and a short PQ interval.The effect of antihypertensive treatment on arterial stiffness and serum concentration of selected matrix metalloproteinases.[The probability of Kawasaki diseases in young patients with cardiac disorders--retrospective studies].Effects of slow deep breathing at high altitude on oxygen saturation, pulmonary and systemic hemodynamicsMain results of the ouabain and adducin for Specific Intervention on Sodium in Hypertension Trial (OASIS-HT): a randomized placebo-controlled phase-2 dose-finding study of rostafuroxin[Hypertension in postmenopausal women --selected pathomechanisms].24-hour central blood pressure and intermediate cardiovascular phenotypes in untreated subjects.Left ventricular diastolic function associated with common genetic variation in ATP12A in a general population.Ambulatory hypertension subtypes and 24-hour systolic and diastolic blood pressure as distinct outcome predictors in 8341 untreated people recruited from 12 populations.Setting thresholds to varying blood pressure monitoring intervals differentially affects risk estimates associated with white-coat and masked hypertension in the populationArterial stiffness, central hemodynamics, and cardiovascular risk in hypertension.Prevalence of left ventricular diastolic dysfunction in European populations based on cross-validated diagnostic thresholds.Cross-sectional and longitudinal assessment of arterial stiffening with age in European and chinese populations.Cardiac Rehabilitation in Real Life.The challenge of blood pressure control in patients with ischaemic heart disease in Europe.Sodium excretion as a modulator of genetic associations with cardiovascular phenotypes in the European Project on Genes in Hypertension.Age and gender dependent heart rate circadian model development and performance verification on the proarrhythmic drug case study.Significance of white-coat hypertension in older persons with isolated systolic hypertension: a meta-analysis using the International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes population.Risk stratification by 24-hour ambulatory blood pressure and estimated glomerular filtration rate in 5322 subjects from 11 populations.Masked hypertension in diabetes mellitus: treatment implications for clinical practice.The pulsatile component of blood pressure: its role in the pathogenesis of atherosclerosis.Association of free testosterone and sex hormone binding globulin with metabolic syndrome and subclinical atherosclerosis but not blood pressure in hypertensive perimenopausal womenHeritability and intrafamilial aggregation of arterial characteristics.Double product reflects the predictive power of systolic pressure in the general population: evidence from 9,937 participantsHow many measurements are needed to estimate blood pressure variability without loss of prognostic information?Iodine-deficiency prophylaxis and the restriction of salt consumption - a 21st century challenge.Outcome-driven thresholds for ambulatory pulse pressure in 9938 participants recruited from 11 populations.From pioneering to implementing automated blood pressure measurement in clinical practice: Thomas Pickering's legacy.Treatment of hypertension in the elderly in 2010 - a brief review.Blood pressure variability in relation to outcome in the International Database of Ambulatory blood pressure in relation to Cardiovascular Outcome.Inflammatory markers 10 weeks after myocardial infarction predict future cardiovascular events.[Impact of chronic Chlamydia pneumoniae infection on left ventricular remodeling after myocardial infarction].Half of coronary patients are not instructed how to respond to symptoms of a heart attack.How drugs influencing central blood pressure prevent atherosclerosis complications?Short-term blood pressure variability in relation to outcome in the International Database of Ambulatory blood pressure in relation to Cardiovascular Outcome (IDACO).The management of cancer patients with heart disease.
P50
Q26827799-1BF6CDC3-769D-4A23-9245-D6814508B64EQ28173906-0DC46E4F-CA96-4B74-8610-57F96C28DB96Q28209012-E6F7172A-7D80-4643-B564-EC2DC3848E13Q31121048-3AD9787E-2419-4F85-A895-9069E9A06606Q33154465-E6D6A0D2-87BD-444E-9980-99F136FCF10AQ33904413-027E2D30-0EB8-4610-B2AF-7BE0D3BAE734Q34310271-DD04EC65-A50A-4F91-B03C-6E799153DA3DQ34477709-AA27A22E-CB6D-4F05-94D8-9AC4D863D7DBQ34540811-42C916E5-2542-48F8-B92A-5F30B57BBD1CQ34654121-6315F604-6EA1-41F1-AA1C-5A02051348C1Q34987397-3655F705-57C8-47CB-8C9B-87FD88767ED2Q35388910-D991D4BD-6D1C-4441-87FC-CFCF21342C42Q35552403-5A2261E5-B5A4-486B-AC36-9DDB9231317DQ35571623-3C6E1F6A-C1AF-412F-8FC2-DE8EB174A094Q35610712-E90C2F1E-3809-4448-B2D0-82F26B917844Q35955411-01BC9A55-35D6-4691-8CE3-8F391B205293Q36033518-BA402294-2FFB-48E0-8A97-9CE835917182Q36195105-3EB9F542-7016-4C0E-A25F-A8764B645353Q36375097-91D3424B-A363-4349-AA13-2442115365ECQ36409926-E449694A-3BF6-4B3E-BC2B-F1828B82A097Q36688587-83630667-DFF4-4FAF-88A9-09D48859F4C9Q36713745-B8A0185E-6B24-48E8-A860-C6829976FD1BQ36713844-3509AA77-BD6A-4E69-BBA0-970968AAB996Q36780516-5E02F7D8-AB62-4185-8028-554FF0CEA490Q36939476-B70F0706-8EC7-45D3-B91A-072E7520E1E1Q36958261-D190BB02-651F-42D5-BDEE-89712974EDDFQ36958283-2603D37B-8CE9-4DAD-A1B0-EE393A7BC45AQ37220724-A24F80F5-0251-4CA4-A310-258924A8E14BQ37359595-B7FEAA07-0B3D-4368-A55E-AE9BF3A9BE1CQ37703082-4B10A3C8-CED0-46AE-A19C-7D9D88098F1CQ37721463-6D41030E-2DF6-43E6-BB0E-24ACE046A843Q37734097-09B64F1D-FDC1-4D41-AF00-B6FB56313E5EQ37748799-CED53D05-12C1-43C2-9400-2731D9296564Q37770960-386156FF-1473-462F-9868-F259D7EEE94AQ37856998-7FCC62C0-1597-4EDF-8AAA-6D47E1704BB0Q37859394-51A7914F-F379-499B-B034-BF1D957EC4B9Q37960404-212B8055-2277-40A1-A501-D2D547937118Q37978943-AC37D933-B031-4D05-BB8E-AFC05967ED81Q37980781-6B7D8220-E021-4F06-BC6E-6EADA9669CCDQ38024361-57884502-CF2F-4F66-9865-97CAEF878FC8
P50
description
investigador
@es
polska lekarka, kardiolog
@pl
researcher
@en
wetenschapper
@nl
name
Kalina Kawecka-Jaszcz
@ast
Kalina Kawecka-Jaszcz
@ca
Kalina Kawecka-Jaszcz
@cs
Kalina Kawecka-Jaszcz
@en
Kalina Kawecka-Jaszcz
@es
Kalina Kawecka-Jaszcz
@gl
Kalina Kawecka-Jaszcz
@hr
Kalina Kawecka-Jaszcz
@hsb
Kalina Kawecka-Jaszcz
@it
Kalina Kawecka-Jaszcz
@nl
type
label
Kalina Kawecka-Jaszcz
@ast
Kalina Kawecka-Jaszcz
@ca
Kalina Kawecka-Jaszcz
@cs
Kalina Kawecka-Jaszcz
@en
Kalina Kawecka-Jaszcz
@es
Kalina Kawecka-Jaszcz
@gl
Kalina Kawecka-Jaszcz
@hr
Kalina Kawecka-Jaszcz
@hsb
Kalina Kawecka-Jaszcz
@it
Kalina Kawecka-Jaszcz
@nl
prefLabel
Kalina Kawecka-Jaszcz
@ast
Kalina Kawecka-Jaszcz
@ca
Kalina Kawecka-Jaszcz
@cs
Kalina Kawecka-Jaszcz
@en
Kalina Kawecka-Jaszcz
@es
Kalina Kawecka-Jaszcz
@gl
Kalina Kawecka-Jaszcz
@hr
Kalina Kawecka-Jaszcz
@hsb
Kalina Kawecka-Jaszcz
@it
Kalina Kawecka-Jaszcz
@nl
P214
P1412
P1559
Kalina Kawecka-Jaszcz
@pl
P21
P214
P27
P31
P496
0000-0002-8660-2867
P735
P7859
lccn-n2013180589